Patents Assigned to PROLYNX LLC
  • METHODS OF TREATING CANCER WITH LONG-ACTING TOPOISOMERASE I INHIBITOR
    Publication number: 20260041680
    Abstract: The disclosure provides method of treating cancer in a patient in need thereof, comprising safely and efficaciously administering to the patient PLX038, a long lasting-PEGylated prodrug of the topoisomerase I inhibitor. The disclosure further provides combination therapies of PLX038 with inhibitors of the DNA damage response (DDR).
    Type: Application
    Filed: August 3, 2023
    Publication date: February 12, 2026
    Applicant: ProLynx LLC
    Inventors: Daniel V. SANTI, Shaun D. FONTAINE, Gary W. ASHLEY
  • TREATING CANCER WITH LONG-ACTING TOPOISOMERASE I INHIBITOR
    Publication number: 20260034120
    Abstract: The disclosure provides method of treating cancer in a patient with ATM-deficient or ATR-deficient tumors, comprising safely and efficaciously administering to the patient PLXO38, a long lasting-PEGylated prodrug of the topoisomerase I inhibitor. The disclosure further provides combination therapies of PLXO38 with inhibitors of the DNA damage response (DDR).
    Type: Application
    Filed: August 3, 2023
    Publication date: February 5, 2026
    Applicant: ProLynx LLC
    Inventors: Daniel V. SANTI, Shaun D. FONTAINE, Gary W. ASHLEY
  • CONJUGATION LINKERS
    Publication number: 20260007768
    Abstract: Provided are ?-eliminative linkers suitable for the conjugation of small molecule, peptide, and protein and compounds comprising the linkers.
    Type: Application
    Filed: May 20, 2025
    Publication date: January 8, 2026
    Applicant: ProLynx LLC
    Inventors: Gary W. ASHLEY, Brian HEARN, Shaun FONTAINE, Eric L. SCHNEIDER
  • Hydrogels with biodegradable crosslinking
    Patent number: 12478680
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: November 25, 2025
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • Conjugated inhibitors of DNA damage response
    Patent number: 12472261
    Abstract: Provided herein are releasable conjugates of inhibitors of DNA damage response suitable for use as therapeutic agents in the treatment of disease.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: November 18, 2025
    Assignee: ProLynx LLC
    Inventors: Shaun D. Fontaine, Brian R. Hearn, Daniel V. Santi
  • PROTOCOL FOR MINIMIZING TOXICITY OF COMBINATION DOSAGES AND IMAGING AGENT FOR VERIFICATION
    Publication number: 20250312498
    Abstract: Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.
    Type: Application
    Filed: March 24, 2025
    Publication date: October 9, 2025
    Applicant: ProLynx LLC
    Inventors: Brian HEARN, Daniel V. Santi, Shaun Fontaine, Gary W. Ashley
  • Conjugation linkers
    Patent number: 12364771
    Abstract: Provided are ?-eliminative linkers suitable for the conjugation of small molecule, peptide, and protein and compounds comprising the linkers.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: July 22, 2025
    Assignee: PROLYNX LLC
    Inventors: Gary W. Ashley, Brian Hearn, Shaun Fontaine, Eric L. Schneider
  • HIGH-THROUGHPUT MICROEMULSIFICATION MEMBRANE
    Publication number: 20240181397
    Abstract: The present disclosure is related to high-throughput membranes for preparation of microdroplet emulsions and microparticle suspensions and apparatus and systems comprising the same. Also provided are methods of preparing microdroplet emulsions and microparticle suspensions.
    Type: Application
    Filed: March 18, 2022
    Publication date: June 6, 2024
    Applicant: ProLynx LLC
    Inventors: Jeffrey C. HENISE, Brian YAO
  • SYNERGISTIC CANCER TREATMENT
    Publication number: 20240082436
    Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.
    Type: Application
    Filed: July 11, 2023
    Publication date: March 14, 2024
    Applicant: ProLynx LLC
    Inventors: Daniel V. SANTI, Shaun FONTAINE
  • EXTENDED RELEASE HYDROGEL CONJUGATES OF C-NATRIURETIC PEPTIDES
    Publication number: 20240041982
    Abstract: Provided herein are extended release hydrogel conjugates of c-natriuretic peptides, methods of preparation thereof, and methods of use thereof.
    Type: Application
    Filed: November 24, 2021
    Publication date: February 8, 2024
    Applicant: ProLynx LLC
    Inventors: Eric L. SCHNEIDER, Brian R. HEARN, Daniel V. SANTI
  • PROTOCOL FOR MINIMIZING TOXICITY OF COMBINATION DOSAGES AND IMAGING AGENT FOR VERIFICATION
    Publication number: 20230321286
    Abstract: Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.
    Type: Application
    Filed: March 7, 2023
    Publication date: October 12, 2023
    Applicant: ProLynx LLC
    Inventors: Brian HEARN, Daniel V. SANTI, Shaun FONTAINE, Gary W. ASHLEY
  • Synergistic cancer treatment
    Patent number: 11730836
    Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 22, 2023
    Assignee: ProLynx LLC
    Inventors: Daniel V. Santi, Shaun Fontaine
  • HYDROGELS WITH BIODEGRADABLE CROSSLINKING
    Publication number: 20230135347
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Application
    Filed: September 7, 2022
    Publication date: May 4, 2023
    Applicant: ProLynx LLC
    Inventors: Gary W. ASHLEY, Daniel V. SANTI, Jeffrey C. HENISE
  • CONJUGATED INHIBITORS OF DNA DAMAGE RESPONSE
    Publication number: 20220331437
    Abstract: Provided herein are releasable conjugates of inhibitors of DNA damage response suitable for use as therapeutic agents in the treatment of disease.
    Type: Application
    Filed: August 28, 2020
    Publication date: October 20, 2022
    Applicant: ProLynx LLC
    Inventors: Shaun D. FONTAINE, Brian R. HEARN, Daniel V. SANTI
  • Hydrogels with biodegradable crosslinking
    Patent number: 11454861
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: September 27, 2022
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • IMPROVED CONJUGATION LINKERS
    Publication number: 20220280654
    Abstract: Provided are ?-eliminative linkers suitable for the conjugation of small molecule, peptide, and protein and compounds comprising the linkers.
    Type: Application
    Filed: April 3, 2020
    Publication date: September 8, 2022
    Applicant: ProLynx LLC
    Inventors: Gary W. ASHLEY, Brian HEARN, Shaun FONTAINE, Eric L. SCHNEIDER
  • STEAM STERILIZATION OF HYDROGELS CROSSLINKED BY BETA-ELIMINATIVE LINKERS
    Publication number: 20220265873
    Abstract: Methods for the steam sterilization of hydrogels crosslinked with a beta-eliminative linker without the drawback of significant degradation are provided.
    Type: Application
    Filed: August 7, 2020
    Publication date: August 25, 2022
    Applicant: ProLynx LLC
    Inventors: Jeffrey C. HENISE, Gary W. ASHLEY, Brian YAO
  • SLOW-RELEASE CYTOKINE CONJUGATES
    Publication number: 20220193253
    Abstract: This disclosure generally relates to releasable cytokine conjugates and methods of using the same.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 23, 2022
    Applicant: ProLynx LLC
    Inventors: John A. HANGASKY, III, Samuel J. PFAFF, Daniel V. SANTI
  • Hydrogels with biodegradable crosslinking
    Patent number: 11179470
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: November 23, 2021
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • Hydrogels with biodegradable crosslinking
    Patent number: 11181803
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: November 23, 2021
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise